Complain about a product or service

FDA Issues Flu Vaccine Guidelines

May 31, 2007

Bird Flu • FDA Gains Insight to Bird Flu Virus • New Flu Bug Proves Resistant to Antiviral Drugs • Report: Nation Not Ready For Flu Pandemic • Antiviral Overuse Could Aid Deadly Flu • 1918 Flu Virus Offers Clues to Prevent Pandemics • Scientists Report Progress Toward Bird Flu 'Cure' • Bird Flu Not the Only Animal Disease Threat • Bird Flu Vaccine Trials 'Encouraging' • FDA Frets about Flu Drugs' Side Effects • World Not Ready For Bird Flu • Researchers: Bird Flu Pandemic Inevitable • Bird Flu Scare in Virginia • FDA Issues Flu Vaccine Guidelines • FDA Approves First Bird Flu Vaccine • More Flu Bugs Show Resistance To Anti-Virals • Seasonal Flu Shot Might Offer Some Bird Flu Protection • Experts Concerned about Tamiflu Overuse • Study Finds Much Bird Flu Planning is Misplaced • U.S. Orders More Bird Flu Vaccine • Scientists Identify Genetic Changes That Could Lead to Bird Flu Pandemic • Drug Interaction Can Render Tamiflu Ineffective • New Bird Flu Variant Renews Pandemic Concerns • Researchers Find New Weapon Against Flu Virus • Researchers Test Spreadability of Bird Flu Viruses to Humans • GlaxoSmithKline Claims Bird Flu Breaththrough • Global Corporations Struggle to Plan For Pandemic • Flu Pandemic Is "Inevitable," EU Experts Warn • Bird Flu Virus May Have Mutated In Indonesian Cases • Indonesian Nurse May Have Bird Flu • Study Warns of "Chaos" and "Panic" If Bird Flu Strikes • Investigators Find No Evidence Bird Flu Virus Has Mutated • Scientists Fear Bird Flu Virus May Have Mutated • Airlines Queasy About Quarantining Bird Flu Victims • More ...

With health officials expressing concern there won’t be enough vaccine available in the event of a flu pandemic, the U.S. Government is counting on technology and innovation to increase supplies.

The Food and Drug Administration has issued final recommendations to increase production and enhance distribution of safe and effective influenza vaccines for both seasonal and pandemic use.

“FDA continues its commitment to help increase the supply of influenza vaccines and support the development of new approaches to vaccine production,” said Jesse L. Goodman, M.D., M.P.H., director of FDA's Center for Biologics Evaluation and Research (CBER).

“Having additional manufacturers of licensed influenza vaccines will enhance the capacity to produce more doses of seasonal influenza vaccines, as well as contribute to the nation's pandemic preparedness, one of our top priorities.”

In March 2006, FDA issued two draft guidance documents for public comment — one for seasonal influenza vaccines and another for pandemic influenza vaccines. The draft documents outline specific approaches for manufacturers to develop new vaccines that are safe, pure, and potent. The final guidances reflect public input, including vaccine companies and public health officials, the agency said.

Both guidances recommend using recent technologies such as cell culture and recombinant manufacturing to enhance the development and evaluation of vaccines. They also recommend adding substances that improve the immune response from the vaccine.

The plans describe conventional and accelerated approval pathways to get vaccines licensed faster. Under the plan, companies selecting the conventional pathway must provide clinical evidence that the vaccine prevents influenza.

Adequate and well-controlled clinical trials are also required for accelerated approval but companies may use a biological indicator — such as immune response to the vaccine — to predict effectiveness, an approach that may reduce the vaccine's development time. Further clinical studies are then required to verify the vaccine's clinical benefit.

The guidelines tell manufacturers they should submit a new Biologics License Application (BLA) for the initial licensure of a pandemic or seasonal influenza vaccine to ensure that each pandemic and seasonal vaccine has its own trade name and labeling.

For companies with U.S. licensed seasonal influenza vaccines, the pandemic guidance outlines the regulatory pathway for obtaining licensure for a new pandemic vaccine in which the manufacturing process is the same as for the seasonal vaccine.

For manufacturers developing vaccines using a new manufacturing process, both guidance documents explain the process for obtaining licensure using the accelerated approval pathway.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.